<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388088</url>
  </required_header>
  <id_info>
    <org_study_id>MED.RES.HOS.2010.02.SKM</org_study_id>
    <nct_id>NCT01388088</nct_id>
  </id_info>
  <brief_title>The Effect of Amiloride and Spironolactone in Patients With Hypertension</brief_title>
  <acronym>hass</acronym>
  <official_title>Effect of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables in Patients With Essential Hypertension in a Doublle-blinded Randomised Placebo-controlled, Cross-over Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erling Bjerregaard Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators wish to investigate the potential effects of potassium. In this study we
      will examine patients with hypertension and increase their potassium-levels using Amiloride
      and Spironolactone.

      The investigators will examine the changes in the cardiovascular system using a
      Sphygmocor-scanner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose of the study is to examine the effect of amilorid and spironolacton on

        1. Renal function (GFR, u-AQP2, u-ENaCÎ², u-cAMP, u-PGE2, CH20, FENa, FEK),

        2. Pulsewavevelocity, augmentation index and centralt bloodpressure,

        3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and

        4. Ambulatory blood pressure
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 years</time_frame>
    <description>24 hours blood pressure measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>2 years</time_frame>
    <description>We will investigate the changes in cardiovascular variables using a Sphygmocor scanner.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Increases the level of potassium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Increases the level of potassium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>25 mg twice a day</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>5 mg twice a day</description>
    <arm_group_label>Amiloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension

          -  Age 45-70

          -  BMI: 18,5-30

        Exclusion Criteria:

          -  Other diseases

          -  Drug or alcohol abuse

          -  Abnormal findings in the screening procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solveig K Matthesen, Cand.Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medical Research</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>July 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>March 27, 2012</last_update_submitted>
  <last_update_submitted_qc>March 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Proffesor</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Potassium</keyword>
  <keyword>Blood-pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

